Journal
AMERICAN JOURNAL OF KIDNEY DISEASES
Volume 68, Issue 2, Pages 296-306Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2016.03.421
Keywords
Acute kidney injury (AKI); colistin; colistin methanesulfonate; polymyxin E; continuous renal replacement therapies (CRRTs); renal toxicity; nephrotoxicity; chronic kidney disease (CKD); critical illness; dialysis; hemofiltration; kidney function; colistin pharmacokinetics; colistimethate; therapeutic drug monitors
Categories
Funding
- Abbott
- BBraun Melsungen
- Baxter-Gambro
- Fresenius
- Otsuka
- Novartis
- Behring
- Chiesi
- Teva
Ask authors/readers for more resources
Colistin (polymyxin E) is a mainly concentration-dependent bactericidal antimicrobial active against multidrug-resistant Gram-negative bacteria. After being abandoned over the past 30 years due to its neuro- and nephrotoxicity, colistin has been reintroduced recently as a last-resort drug for the treatment of multidrug-resistant Gram-negative bacteria infections in combination with other antimicrobials. Unfortunately, although renal toxicity is a well-known dose-related adverse effect of colistin, relatively few studies are currently available on its peculiar pharmacodynamic/pharmacokinetic properties in clinical settings at high risk for drug accumulation, such as acute or chronic kidney disease. In these specific contexts, the risk for underdosing is also substantial because colistin can be easily removed by dialysis/hemofiltration, especially when the most efficient modalities of renal replacement therapy (RRT) are used in critically ill patients. For this reason, recent recommendations in patients undergoing RRT have shifted toward higher dosing regimens, and therapeutic drug monitoring is advised. This review aims to summarize the main issues related to chemical structure, pharmacodynamics/pharmacokinetics, and renal toxicity of colistin. Moreover, recent data and current recommendations concerning colistin dosing in patients with reduced kidney function, with special regard to those receiving RRT such as dialysis or hemofiltration, are also discussed. (C) 2016 by the National Kidney Foundation, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available